Federal Equipment Company is a reliable resource for pharmaceutical and biopharmaceutical processing and packaging equipment needs, with over 65 years of expertise working with manufacturers seeking to buy and sell used equipment. For companies with surplus equipment, Federal Equipment Company takes away all the headaches of asset management. We bring deep knowledge of equipment values, supporting accurate appraisals, and advise you on a range of options to optimize the value you recoup. We also offer cash liquidity and fast, expert removal of individual pieces to entire lines – protecting your facility. This activity with reputable companies gives us a continual on-hand inventory of reliable equipment manufactured by leading OEMs. Our market knowledge ensures you buy exactly what you need with fast turnaround. We also offer expert training & troubleshooting for solid dose equipment. | Federal Equipment Company is a trusted source for premium used biotechnology equipment. Recognizing the advanced technologies and precision essential in biotech and biopharmaceutical production, we have methodically curated our inventory to align with the high standards and demands of this pioneering industry sector. Connect with our expert team at BIO International 2025 for a detailed quote on our available biotechnology equipment! | Since 1957, Federal Equipment Company has been a trusted supplier of high-quality used processing and packaging equipment for the plastics and rubber industries. We help manufacturers quickly and reliably source cost-effective machinery for extrusion, compounding, film and sheet, recycling, and downstream converting. Our extensive inventory includes ready-to-ship extruders (single- and twin-screw), pelletizers, blown and cast film systems, granulators, mixers, screeners, and more. We stock equipment from leading OEMs like Davis-Standard, Erema, Cumberland, and Farrel, with detailed listings and photos available at fedequip.com. Buyers choose us for our transparency, speed, and deep industry knowledge. In addition to equipment sales, we offer asset recovery services that help plastics manufacturers maximize value from surplus equipment through resale, redeployment, or auction. Whether you’re scaling production or clearing idle assets, our team delivers dependable solutions and responsive service. Visit us at the AMI Plastics World Expos 2025 or browse our inventory online at fedequip.com.
FAREVA
Farera as a CDMO is providing a large service offer as sterile injectable and high potent, biological drug, conventionnal product, medial devices, foods supllements and probiotics as well as Drug substance manufacturing of recombinant protein, Andibody Dug Conjugason (ADC) with the associated Fill& Finish | FAREVA is a leading global pharmaceutical CDMO with industry leading capabilities in the development and manufacturing of a large range of Drug Products and Active Pharmaceutical Ingredients (APIs). FAREVA employs 13,000 people distributed in 41 production sites located in 13 countries in EMEA and the Americas. 16 of the FAREVA sites are dedicated to pharmaceutical activities. FAREVA’s API division has operations in 3 European sites located in France and Germany. | Fareva is a leading global pharmaceutical CDMO with a network of 16 manufacturing sites and 3 development sites throughout EMEA and the Americans. We offer comprehensive drug product and API services, including formulation development, clinical manufacturing, scale-up, and commercial manufacturing of small and large molecules. Our capabilities cover a wide range of dosage forms, such as OTC products, oral solid doses, non-sterile liquids and solids, ophthalmics, as well as sterile fill/finish and lyophilized presentations. In addition, our facilities have extensive expertise in secondary packaging, enabling us to serve as a fully integrated partner for our clients’ end-to-end pharmaceutical needs.
EXO BIOLOGICS
EXO Biologics is a Belgian clinical stage biotech focused on the development and the supply of exosomes and extracellular vesicles therapies. EXO biologics is the 1st company in the world to ever enter EU clinical trial with MSC derived exosomes, thus paving the European regulatory pathway for exosomes (EVENEW study). Our lead asset EXOB-001 is in phase I/II for Bronchopulmonary Dysplasia (orphan disease). EXOB-001 can be used for variety of other indications due to its safety profile and immunomodulator effect (CNS, inflammatory, Gastroenterology ,…). Our GMP manufacturing platform ExoPulse™ is accessible to all exosome developers through our wholly owned subsidiary ExoXpert. ExoXpert is the only CDMO with an exosome platform used in EU clinical trials. | Exo Biologics is a clinical-stage company based in Belgium and a pioneer in the extracellular vesicle (EV) field. The company is currently evaluating its lead asset, EXOB-001, in a Phase I clinical trial in the EU, conducted across multiple centers. EXOB-001 is composed of EVs derived from mesenchymal stem cells (MSCs) and is being developed to treat bronchopulmonary dysplasia (BPD)—a rare inflammatory lung disease affecting preterm infants. EXOB-001 is the first MSC-EV-based product to enter clinical trials in the EU, positioning Exo Biologics as the most advanced company in this field to date. Exo Biologics offers exosomes specialized CDMO services through its subsidiary ExoXpert
ExcellGene
ExcellGene is a leading biotechnology company specializing in developing and producing high-quality recombinant proteins and monoclonal antibodies, with expertise in CHO and HEK-293 cell lines. With over 20 years of experience in the field, our dedicated team of experts ensures reliable, timely, and efficient customized solutions meeting the highest quality standards for a wide range of research, diagnostic, and therapeutic applications. Visit our booth #1743 to learn more about our services and products, and go to www.excellgene.com for additional information or to get in touch. | ExcellGene is a leading biotechnology company specializing in developing and producing high-quality recombinant proteins and monoclonal antibodies, with expertise in CHO and HEK-293 cell lines. With over 20 years of experience in the field, our dedicated team of experts ensures reliable, timely, and efficient customized solutions meeting the highest quality standards for a wide range of research, diagnostic, and therapeutic applications. | Looking for a trusted partner in the development of cell lines and manufacturing processes? Look no further. With over 20 years of experience, we specialize in high-yielding (5-14 g/L), GMP-ready, CHO, and HEK293 cell lines for the production of biologics, biosimilars, and gene therapy (AAV, Adenovirus). We have a proven track record of expressing all types of proteins, including bi-specific mAb, Fc-fusions, viral proteins, cytokines, and more. Our team of scientists is ready to support your project from start to finish, including process development, analytical methods, scale-up, tox-batches, and Master Cell Banking. At our company, we pride ourselves on our commitment to quality and customer satisfaction. Contact us today to see how we can help you achieve your goals and be your trusted partner in cell line and process development.
Evonik Corp
“Evonik is active in more than 100 countries around the world and goes far beyond chemistry to create innovative, profitable, and sustainable solutions for our customers. Evonik’s Health Care business line is a global innovation hub for the world’s leading life science companies from the pharmaceutical, nutraceutical and medical device industries. We support customers along the entire product cycle from early development to commercial manufacturing. Our system solutions are backed by the scientific excellence of our interdisciplinary and diverse teams.” | Evonik Health Care offers a broad portfolio of cell culture ingredients and related services as a technology platform which contributes to highly effective drug development. Our cell culture solutions can be used in the manufacturing of therapeutic proteins like monoclonal antibodies, as well as in the production of viral vectors for gene therapy and specific cells for cell therapy. Our portfolio helps you to ensure optimal growth and viability of cells, enabling the efficient production of biopharmaceutical drugs. The Evonik production network relies on decades-long manufacturing experience and an excellent degree of backward integration to ensure the highest level of quality control and the reliable supply of critical cell culture ingredients. Are you faced with upstream challenges in cell culture? Our Global Competence Network for Cell Culture Solutions is your primary resource when you are looking for system solutions to enhance your media and processes. Whether you would like to intensify a process or scale it up, our multidisciplinary team is ready to help. Our network includes experts in business, application technology, and research and development covering chemistry, cell biology, bioprocessing and media optimization. Our commitment to innovation extends beyond our products. As a solutions provider, we are dedicated to helping biopharma companies and media manufacturers navigate the complex regulatory environment and market access challenges. Building up on our strong expertise in biotechnology and biosolutions, we provide application support and media formulation guidance to help you boost the cell culture performance while reducing complexity and cost of biopharma production. | The Health Care business at Evonik is a global innovation hub for the world’s leading life science companies. We support customers across the entire product lifecycle – from early development to commercial manufacturing – with a broad portfolio of advanced drug delivery technologies, CDMO services for APIs and HPAPIs, and high-performance biopharma solutions. Backed by scientific excellence, sustainability, and a trusted network of western-based facilities, we help the world’s leading life science companies accelerate innovation and improve patient outcomes – today and tomorrow. Evonik is a leading global specialty chemicals company headquartered in Essen, Germany, operating in over 100 countries. Focused on high-growth megatrends like health, nutrition, and sustainability, Evonik develops innovative, tailor-made products for industries ranging from pharmaceuticals and automotive to agriculture. | Evonik is a leading specialty chemical manufacturer of additives, bismaleimide resins, thermoplastic resins and semi-finished products used in composite products and markets worldwide. | Discover Smart Effects, where innovation meets sustainability. Our advanced solutions, leveraging the synergy of silica and silanes, cater to diverse industries including green mobility, agriculture, and food. By utilizing cutting-edge technologies and efficient processes, Smart Effects delivers exceptional value and performance. We are committed to driving positive change with eco-friendly products that benefit both our customers and the planet. Join us in shaping a smarter, greener future with Smart Effects. | For more than 50 years Evonik has served customers worldwide with innovative products and services for medical devices. With our global team of experts we support you at every stage of your product development. We offer a comprehensive portfolio of customized biomaterials and services that open up new possibilities for patient-specific treatment, empowering our customers to bring their ideas to life. | Evonik’s performance additives and dispersing agents for the plastics industry improve the production process and final quality of products. With ongoing challenges around upcoming regulations, the cost and availability of raw materials, and reducing energy use, the plastics industry continues to come under increasing pressure to improve sustainability through better recycling, waste reduction and resource efficiency. The only way to achieve all of this is through continuous innovation. | Evonik Care Solutions is a leading sustainable specialties partner for companies in the beauty and personal care industries. Evonik offers a broad portfolio of innovative ingredients, technologies, and services that enable customers to achieve superior sustainability and functionality in their formulations. Recognized as a powerhouse and global leader, Evonik operates across a diverse range of markets and applications, including active ingredients, active delivery systems, skin care, sun care, color cosmetics, hair care, skin cleansing, alternative preservation, and product stability. | Evonik provides market-relevant and technologically differentiated products for the personal care and oral care industries. Evonik’s Care Solutions portfolio includes solutions for formulation design, innovative emulsifiers, emollients, product protection, natural alternative preservatives, and active ingredients, including clinically-tested ceramide, peptide, delivery system, and botanicals. Evonik Silica’s broad and diverse portfolio is designed to fit consumer’s needs in silica shape, size, distribution, flexibility, compatibility, and application skin-feel and appearance, providing personal care solutions for skincare, decorative cosmetics, rinse-off formulations, and oral care solutions for whitening and sensitive toothpastes. | Evonik Industries, a global chemical company, develops and manufactures specialty chemicals for various products and markets worldwide.Providing solutions to the packaging industry, Evonik’s Coating & Adhesive Resins Business Line offers DEGACRYL® HS, a range of methacrylic polymers for applications like dairy or pharmaceutical packaging.DEGACRYL® HS binders are THE major ingredient for high-quality coatings and are known for their secure seal and smooth peel capabilities. DEGACRYL® HS not only offers direct adhesion to aluminum, PET and paper, but also seals to all common substrates, like polystyrene, polypropylene, polyethylene and many more – all while being free of styrene and PVC.In order to reduce plastic waste, Evonik offers sustainable DEGACRYL® HS grades that enable NIR sorting of plastics and improve recycling efficiency by enabling mono material packaging. Furthermore, recyclability of paper packaging coated with DEGACRYL® HS is possible without having to compromise seal strength or barrier properties. | Evonik is a world leader in the manufacture of high performance products supporting lightweight design, 3D printing and efficient production of fiber-reinforced composites. It supplies foam core materials for sandwich construction, plus thermoplastic & thermosetting resin matrices and their components, including crosslinkers, catalysts, methacrylates, impact strength modifiers and process additives. | Evonik’s High Performance Polymers takes you on the move with its solutions for electric and hybrid vehicles. When developing today’s high-voltage automotive electrical systems, manufacturers rely on VESTAMID® polyamide 12 for the most crucial electric vehicle battery components including busbars and cooling lines for battery packs, and VESTAKEEP® for wire windings in electric motors. | Evonik Protectosil(R) portfolio of water repellents, corrosion inhibitors, ANTIGRAFFITI(R) and easy to clean products are designed to protect and preserve precast and masonry.
Eurogentec
Eurogentec is an international company founded in 1985 and part of Kaneka Corp. since 2010. Headquartered in Liege (Belgium) it provides products and services to scientists involved in the life science research, molecular diagnostics and therapeutic developments. Eurogentec has production sites in Europe and United States of America. The company is recognized as one of the major suppliers in the field of genomics and proteomics as well as a trusted US FDA inspected Contract Development and Manufacturing Organization (CDMO) for the bio-production of pharmaceuticals (vaccines and medicines). | Founded in 1985 and part of Kaneka Corporation since 2010, Eurogentec is a leading biotechnology and CDMO company specializing in GMP-certified manufacturing of starting materials and APIs. With facilities in Europe and the USA, we support plasmid DNA, mRNA, recombinant proteins, peptides, antibody fragments, and therapeutic oligonucleotides from early research to clinical and commercial production. Our expertise in process development and scale-up ensures high-quality solutions at every stage. Detailed Description of Products (Event Specific) max 500 characters in English – Plasmid DNA : Starting material & APIs including Nano-plasmids & Minicircle DNA. FastTrack: 4-month production. – mRNA : IVT mRNA (0.1g–50g), saRNA, gRNA with co-/post-transcriptional modifications. – Proteins : GMP production in E. coli & P. pastoris for biotech & pharma. – Conjugates : Chemically modified recombinant proteins for clinical use. – Therapeutic Oligos : ASOs, siRNA, aptamers, CpG oligos. – Peptides : Linear, cyclic & complex-modified. – Antibody Fragments : scFv, Fab, VHH, bispecifics. | Eurogentec—part of Kaneka Corp. since 2010—is a leading international company founded in 1985 and headquartered in Belgium. Accredited by the Belgian AFMPS, US FDA, and Japanese MHLW, we deliver trusted solutions to the life sciences, molecular diagnostics, and therapeutic development sectors. As a major supplier in genomics (oligonucleotides, qPCR kits, reagents) and proteomics (custom and catalog antibodies, peptides), we also act as a reliable CDMO for process development and GMP manufacturing of vaccines and medicines—including therapeutic oligonucleotides, peptides, plasmids, recombinant proteins, mRNA and VHH antibodies. Our comprehensive services cover process transfer, development and optimization, scale-up, tox and clinical batches, GMP and GMP-like manufacturing, Quality Control, QA release, and ICH stability studies. From early-phase development to commercialization, Eurogentec is your single partner for every step of the journey.
etherna
We are an RNA technology company, with over 30 years’ experience, offering professional partnerships to pharma and biotech with an emerging or established interest in RNA therapeutics. Our expert team supports start-up, early stage, and late stage projects using our proprietary platforms across RNA chemistry, LNP formulation, and Process Technology, to drive new pipeline development or resolve manufacturing challenges for our partners. | Driving discovery and solving challenges for partners across LNP formulation and RNA chemistry to enable delivery of cost-effective, differentiated and efficacious RNA therapeutics.
EPIC-CRO Research
EPIC RESEARCH CRO “We are focused on providing a full range of tailored, efficient, high-quality, and cost-effective clinical development, regulatory, and post-approval services to the Pharmaceutical, Biotech, Medical Device, and Nutriceutical industries. At EPIC, we help develop and bring new molecules and developments to the regulatory process through trial design, management, site selections, CRFs, ICF, and other material developments emphasizing collaborative work with your team and our clinical and regulatory experts to ensure cost-effective results.” | Clinical trial planning and design: We can help you develop and bring your trial strategy and design to life through collaborative work with your team and our clinical and regulatory experts to ensure cost-effective results. Phase I-IV: From single site to multi-site and multi-national trials, we have the expertise to conduct your trials successfully. Protocol development: Our team of experts will design a protocol that will meet all your clinical development needs for any phase of study. Clinical monitoring: Our clinical research associates receive expert training to ensure that your clinical trials are conducted in strict accordance with the protocol, GCPs and all applicable regulations. Regulatory Affairs: Our team of regulatory experts will handle all regulatory procedures with Ethics Committees and Regulatory Authorities from study start up to study close out. Safety and Pharmacovigilance: Our staff will take care of all requirements for AE and SAE reporting to Ethics Committees and regulatory authorities, as well as annual safety, final reports and DSURs Trial Feasibility Assessment: As time goes by clinical trials become more complex along with subject selection criteria, in a collaborative effort we can help you determine your trial’s feasibility and make the necessary adaptations in the design to ensure your study’s success. Early phase services that include: Design and execution of pre-clinical trials, Phase I protocol development and execution, medical writing, monitoring, data management, biostatistics and clinical pharmacology.
Enzymaster Deutschland GmbH
Enzymaster is a one stop solution provider for the development and commercialization of innovative and sustainable enzyme catalysis technologies. With our proprietary BioEngine® platform and long-term experience, we offer R&D services with establishment of complete technology transfer packages and manufacturing collaborations to fine chemical, pharmaceutical and other industries. Our portfolio includes: • Enzyme panel screening • Smart engineering of enzymes • Process development • Enzyme preparation by fermentation • Biocatalytic manufacturing • Enzyme Kits BioEngine® is our enzyme directed evolution platform, spearheaded by the integration of bioinformatics database guided design, computer protein modelling and simulations, as well as high throughput systems, thus highly efficient and reliable. The application of bioinformatics-assisted design and analysis of protein mutations leads to major time savings and higher success rates; whereas the automated and controlled laboratory procedures deliver higher accuracy and consistency of experimental results. | Enzymaster is a one stop solution provider for the development and commercialization of innovative and sustainable enzyme catalysis technologies. With our proprietary BioEngine® platform and long-term experience, we offer R&D services with establishment of complete technology transfer packages and manufacturing collaborations to fine chemical, pharmaceutical and other industries. Our portfolio includes: • Enzyme panel screening • Smart engineering of enzymes • Process development • Enzyme preparation by fermentation • Biocatalytic manufacturing • Customized and off-the-shelf enzyme kits BioEngine® is our enzyme directed evolution platform, spearheaded by the integration of bioinformatics database guided design, as well as computer protein modelling and simulations, thus highly efficient and reliable. The application of bioinformatics-assisted design and analysis of protein mutations leads to major time savings and higher success rates; whereas the automated and controlled laboratory procedures deliver higher accuracy and consistency of experimental results. To better serve our global customers, we have established a new independent R&D center in Germany. This facility provides contract research (CRO) services and supports smaller-scale production campaigns, offering a fast and flexible solution for enzyme and process development. At the same time, we continue to leverage cost-effective and rapid scale-up solutions in Asia for enzyme manufacturing and chemical production, ensuring efficiency at every stage of the process. Enzymaster strives to contribute to a greener environment and improve manufacturing processes by helping organisations leverage the benefits of biocatalysts, decreasing dependence on toxic and often inefficient, purely chemical syntheses. Flexible fee-for-service models moving in lockstep with R&D programmes, high success rates, commitment to confidentiality, and the avoidance of one-size-fits-all IP policies allow Enzymaster to advance biocatalysis innovation rather than impede it, ultimately fuelling the future of manufacturing.
Enzene
Enzene is an end-to-end CDMO with services spanning discovery, development, and commercial supply, operating integrated sites in Pune (India) and New Jersey (USA). As a pioneer in next-generation biologics technologies, Enzene is disrupting the existing biologics manufacturing paradigm with its patented EnzeneX™ technology, which was the first fully-connected continuous manufacturing™ (FCCM™) platform validated for commercial biologics supply. We partner with innovators and biosimilar developers to deliver accelerated time-to-market, increased production yields, and cost reductions across a broad range of biologic modalities. Committed to pushing the boundaries of biologics manufacturing innovation, Enzene is striving to reduce monoclonal antibody production costs to below $40 per gram by 2025. Our microbial and mammalian drug substance plants, as well as our sterile fill & finish plant in India are EU-GMP certified. | Enzene is a leading global continuously innovative development and manufacturing organization (CIDMO). The company was founded on a belief that we have a responsibility to positively impact healthcare around the world by providing the technological expertise, passion for innovation, and dedication to helping clients bring accessible and affordable products to market. Built on a proven history of successful commercial launches and a strong early-stage product pipeline, Enzene continues to disrupt the CDMO industry with novel processes that improve quality and productivity while reducing costs and carbon footprint. Our comprehensive capabilities encompass R&D, analytics, and GMP manufacturing, empowering us to offer innovative, high-quality solutions that meet diverse client needs. By providing end-to-end CDMO services for biologics, from cell line development to fill & finish for complex molecules, we are a versatile CDMO partner for our clients across a wide array of modalities. And with multiple manufacturing lines at our Pune, India and New Jersey, USA facilities, Enzene is strategically positioned to meet the escalating demand for biologics and biosimilars across both hemispheres. Additionally, our proprietary continuous manufacturing technology, EnzeneX™, sets us apart as visionaries in the industry, driving healthcare advancement and setting new standards for biologics development and manufacturing. The EnzeneX™ platform optimizes quality, efficiency, and flexibility while supporting cost-effective, sustainable production of top-tier biologics, thereby improving global patient access. At Enzene, we are leaders who seek to solve today’s biotech challenges as well as tomorrow’s by upholding our core values of innovation, integrity, excellence, entrepreneurship, candor, and respect.